Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer
Season 4, Episode 44, Mar 29, 2021, 08:00 PM
Dr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.